Otsuka Targets Apotex In Latest Suit Over Generic Abilify
Law360, New York (September 12, 2012, 1:10 PM EDT) -- Otsuka Pharmaceutical Co. Ltd. on Monday continued in its crusade to protect the patents underlying the drug Abilify, alleging in New Jersey federal court that Apotex Corp. is attempting to bring a generic version of the schizophrenia treatment to market before these patents expire.
In its latest attempt to protect the intellectual property associated with its schizophrenia drug, Otsuka alleges that its generic competitor is seeking approval from the U.S. Food and Drug Administration to sell a knockoff version of Abilify. Otsuka said that if Apotex wins approval to sell its own version of Abilify, the generic drug and its manufacturer...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!